New perspectives in managing myeloproliferative disorders: focus on the patient
Copyright policy )New perspectives in managing myeloproliferative disorders: focus on the patient
AbstractRisk stratification is the basis for treatment decisions in the chronic myeloproliferative disorders, and in addition to the three established risk factors of previous thrombosis, age and platelets >1500 × 109, cardiovascular risk factors should be addressed. In addition, premorbidity with regard to possible side effects of platelet‐reducing drugs as well as the impact on quality of life of such side effects should be considered. The near‐to‐normal life expectancy and long term nature of treatment also makes it necessary to consider the potential leukaemogenic effects of some cytostatic drugs. Copyright © 2009 John Wiley & Sons, Ltd.
- Akademiska Barnsjukhuset Sweden
- Uppsala University Hospital Sweden
Myeloproliferative Disorders, Risk Factors, Quality of Life, Disease Management, Humans, Antineoplastic Agents, Risk Assessment
Myeloproliferative Disorders, Risk Factors, Quality of Life, Disease Management, Humans, Antineoplastic Agents, Risk Assessment
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!